



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/544,241	01/03/2006	Yuqiang Wang	53233-00009 US	4750

48423 7590 08/20/2008  
KIRKPATRICK & LOCKHART PRESTON GATES ELLIS LLP  
ATTN: Daniel S. Kim  
1900 MAIN STREET  
SUITE 600  
IRVINE, CA 92614-7319

EXAMINER
----------

CORDERO GARCIA, MARCELA M

ART UNIT	PAPER NUMBER
----------	--------------

1654

MAIL DATE	DELIVERY MODE
-----------	---------------

08/20/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/544,241

**Applicant(s)**

WANG ET AL.

**Examiner**MARCELA M. CORDERO  
GARCIA**Art Unit**

1654

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-30 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-30 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_.

### **DETAILED ACTION**

Claims 1-30 are pending in the application.

Upon reconsideration, the restriction requirement dated 3 March 2008 is herein withdrawn and replaced by the following restriction requirement.

#### ***Election/Restrictions***

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-26 in part, drawn to a system for treating or preventing atherosclerosis providing interventional medical care to a patient.

Group II, claim(s) 1-26 in part, drawn to a system for treating or preventing stenosis providing interventional medical care to a patient.

Group III, claim(s) 1-26 in part, drawn to a system for treating or preventing restenosis providing interventional medical care to a patient.

Group IV, claim(s) 1-26 in part, drawn to a system for treating or preventing smooth muscle cell proliferation providing interventional medical care to a patient.

Group V, claim(s) 1-26 in part, drawn to a system for treating or preventing other abnormal luminal cellular proliferation condition providing interventional medical care to a patient.

Group VI, claim(s) 27-30 in part, drawn to a method for treating or preventing atherosclerosis.

Group VII, claim(s) 27-30 in part, drawn to a method for treating or preventing stenosis.

Group VIII, claim(s) 27-30 in part, drawn to a method for treating or preventing restenosis.

Art Unit: 1654

Group IX, claim(s) 27-30 in part, drawn to a method for treating or preventing smooth muscle cell proliferation.

Group X, claim(s) 27-30 in part, drawn to a method for treating or preventing other abnormal luminal cellular proliferation condition

The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the technical feature of Groups I-II is a system for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, or other abnormal luminal cellular proliferation condition, which is known in the art (See, e.g., WO 00/00238 A1, e.g., pages 1-18 and figures, cited in the IDS of 05/03/06 which teaches a stent with camptothecin to prevent / treat restenosis, e.g., claims 12-13, Example 8) and therefore is not a special technical feature. Since no "special" technical feature is present, there is no Unity of Invention. Examiner has therefore restricted among the different illnesses to be treated since they are drawn to patient populations which are distinct from each other, e.g., a patient with atherosclerosis does not necessarily have restenosis and vice versa. A patient with stenosis does not necessarily have smooth luminal cellular proliferation condition and so forth. A patient with smooth cell proliferation does not necessarily have restenosis or vice versa. A patient with smooth cell proliferation does not necessarily have another abnormal luminal cellular proliferation condition and vice versa.

This application also contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

The many and multiple local delivery systems (e.g., claim 26);

The many and multiple interventional medical devices (e.g., claims 24-25, 29);

The many and multiple bioactive agents (e.g., claims 1-24, 27).

Applicant is required, in reply to this action, to elect a single species [i.e., elect a single and specific local delivery system, a single and specific interventional medical device and a single and specific bioactive agent with all its substituents fully accounted for] to which the claims shall be restricted if no generic claim is finally held to be

Art Unit: 1654

allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

The many and multiple local delivery systems (e.g., claim 26);

The many and multiple interventional medical devices (e.g., claims 24-25, 29);

The many and multiple bioactive agents (e.g., claims 1-24, 27).

The following claim(s) are generic: 1-30.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The aforementioned species are drawn to materially different compositions, delivery agents, interventional medical devices and to functionally different illnesses. The search for each of the above species is not co-extensive particularly with regard to the literature search. Further, a reference which would anticipate one species would not necessarily anticipate or even make obvious another species. Finally, the consideration for patentability is different in

each case. Thus, it would be an undue burden to examine all of the above species in one application.

Because these species are materially and functionally distinct for the reasons given above and the search required for each species is not necessarily required for the other species, election for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise

require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marcela M. Cordero Garcia whose telephone number is (571) 272-2939. The examiner can normally be reached on M-Th 7:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia J. Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1654

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Marcela M Cordero Garcia/  
Examiner, Art Unit 1654

MMCG 08/08